sorafenib has been researched along with glutamine in 6 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (glutamine) | Trials (glutamine) | Recent Studies (post-2010) (glutamine) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 19,062 | 787 | 5,408 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 4 (66.67) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Choi, YK; Ham, HJ; Jang, SY; Jeon, HJ; Kim, BG; Kim, JG; Kim, JH; Kim, MJ; Lee, IK; Lee, JY; Park, KG; Park, SY | 1 |
Dai, W; Dong, L; Guo, C; Guo, H; Liu, H; Liu, T; Shen, X; Song, G; Weng, S; Xu, L; Yu, X; Zhang, G; Zhu, J | 1 |
Gan, B; Koppula, P; Zhuang, L | 1 |
Chakraborti, A; Dhiman, RK; Kanthaje, S; Kaur, R; Taneja, S | 1 |
Ding, J; Li, D; Lin, B; Luo, J; Shang, M; Wang, W; Xu, K; Zheng, S; Zhou, L | 1 |
2 review(s) available for sorafenib and glutamine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Cystine; DNA Methylation; Ferroptosis; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glutathione; Histones; Humans; Molecular Targeted Therapy; Neoplasms; Piperazines; Signal Transduction; Sorafenib; Sulfasalazine | 2021 |
4 other study(ies) available for sorafenib and glutamine
Article | Year |
---|---|
PPARĪ“ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutamine; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; PPAR delta; Random Allocation; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2017 |
OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cohort Studies; Drug Resistance, Neoplasm; Female; Gene Silencing; Glutamine; Humans; Ketoglutarate Dehydrogenase Complex; Lipid Metabolism; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
Topics: Autophagy; Carcinoma, Hepatocellular; Cell Line; Chloroquine; Gene Expression Regulation, Neoplastic; Glutamine; Humans; Liver Neoplasms; MicroRNAs; Sorafenib | 2022 |
SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.
Topics: Carcinoma, Hepatocellular; Glutamine; Histone-Lysine N-Methyltransferase; Humans; Liver Neoplasms; Sorafenib | 2022 |